Brought to you by 
DNAtrix licenses myxoma virus from Univ. of FL for use in oncolytic immunotherapies
07 Dec 2016
Executive Summary
DNAtrix Inc. licensed exclusive rights to the University of Florida’s myxoma virus technology for use in developing oncolytic immunotherapies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement